Association of extended interleukin-10 promoter haplotypes with disease susceptibility and manifestations in German patients with systemic lupus erythematosus

Abstract

Objectives

Associations of interleukin-10 (IL-10) promoter single nucleotide polymorphisms (SNPs) and their haplotypes with systemic lupus erythematosus (SLE) are unclear. We extended the analysis of established proximal IL-10 promoter haplotypes to a more distal SNP with functional capacity.

Methods

Two hundred and ten German caucasian SLE patients fulfilling the ACR criteria and 160 ethnically, age and sex matched controls were genotyped for IL-10 −2849 G > A, −1082 A > G, −819 T > C and −592 C > A. Haplotypes were reconstructed via a mathematical model, then allele and haplotype distributions were compared between patients and controls and patients with different disease manifestations.

Results

We detected at −2849, −1082, −819 and −592 the four predominant haplotypes GGCC (22% in patients vs. 29% in controls), AGCC (24% vs. 21%), GACC (30% vs. 25%) and GATA (24% vs. 24%). GGCC was underrepresented in SLE patients, suggesting a protective effect (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.48–0.94). AGCC was found significantly more frequently in patients with pathognomonic anti-dsDNA antibodies (26% vs. 15%; OR 1.98, 95% CI 1.04–3.75). As compared to patients with glomerulonephritis type V (WHO classification), the presumptive IL-10 high producer allele −2849 G was found significantly more often in patients with GN type III/IV (93% vs. 60%; OR 8.7, 95% CI 1.59–47.15).

Conclusion

Our data confirm that the complexity of the IL-10 promoter evokes the need for a meticulous analysis of its haplotypic structure in order to specify disease associations, particularly under functional aspects, thereby shedding light on the pathophysiology of SLE.

Keywords

SLE immunogenetics cytokines genetic polymorphism disease susceptibility interleukin-10

Get full access to this article

View all access options for this article.

References

Mok

Lau

. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481–490.

Prokunina

Alarcon-Riquelme

. The genetic basis of systemic lupus erythematosus–knowledge of today and thoughts for tomorrow. Hum Mol Genet 2004; 13(Suppl 1): R143–R148.

Tsokos

. Systemic lupus erythematosus. N Engl J Med 2011; 365: 2110–2121.

Manolio

Collins

Cox

. Finding the missing heritability of complex diseases. Nature 2009; 461: 747–753.

Sabat

Grutz

Warszawska

. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331–344.

Fiorentino

Zlotnik

Vieira

. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 3444–3451.

de Waal

Haanen

Spits

. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915–924.

Fiorentino

Bond

Mosmann

. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081–2095.

Wanidworanun

Strober

. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis. J Immunol 1993; 151: 6853–6861.

10.

Rousset

Garcia

Defrance

. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1992; 89: 1890–1893.

11.

Ding

Linsley

Huang

Germain

Shevach

. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224–1234.

12.

De Waal Malefyt

Yssel

De Vries

. Direct effects of IL-10 on subsets of human CD4 + T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754–4765.

13.

Llorente

Richaud-Patin

Wijdenes

. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993; 4: 421–427.

14.

Llorente

Richaud-Patin

Fior

. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37: 1647–1655.

15.

Llorente

Zou

Levy

. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995; 181: 839–844.

16.

Horwitz

Gray

Behrendsen

. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998; 41: 838–844.

17.

Houssiau

Lefebvre

Vanden Berghe

Lambert

Devogelaer

Renauld

. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393–395.

18.

Hagiwara

Gourley

Lee

Klinman

. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996; 39: 379–385.

19.

Park

Lee

Kim

Lee

Song

. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998; 16: 283–88.

20.

Capper

Maskill

Gordon

Blakemore

. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin Exp Immunol 2004; 138: 348–356.

21.

Chun

Chung

Kim

. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007; 27: 461–466.

22.

Llorente

Richaud-Patin

Garcia-Padilla

. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000; 43: 1790–1800.

23.

Miles

Isenberg

. A review of serological abnormalities in relatives of SLE patients. Lupus 1993; 2: 145–150.

24.

Llorente

Richaud-Patin

Couderc

. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1429–1435.

25.

Llorente

Richaud-Patin

. The role of interleukin-10 in systemic lupus erythematosus. J Autoimmun 2003; 20: 287–289.

26.

Westendorp

Langermans

Huizinga

. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349: 170–173.

27.

Gateva

Sandling

Hom

. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009; 41: 1228–1233.

28.

Eskdale

Kube

Tesch

Gallagher

. Mapping of the human IL10 gene and further characterization of the 5' flanking sequence. Immunogenetics 1997; 46: 120–128.

29.

Schotte

Gaubitz

Willeke

. Interleukin-10 promoter microsatellite polymorphisms in systemic lupus erythematosus: association with the anti-Sm immune response. Rheumatology (Oxford) 2004; 43: 1357–1363.

30.

Turner

Williams

Sankaran

Lazarus

Sinnott

Hutchinson

. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1–8.

31.

Edwards-Smith

Jonsson

Purdie

Bansal

Shorthouse

Powell

. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526–530.

32.

Lazarus

Hajeer

Turner

. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997; 24: 2314–2317.

33.

Rood

Keijsers

Van der Linden

. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis 1999; 58: 85–89.

34.

Lopez

Gutierrez

Suarez

. IL-10 and TNFalpha genotypes in SLE. J Biomed Biotechnol 2010; 2010: 838390. DOI: 10.1155/2010/838390–838390. DOI: 10.1155/2010/838390.

35.

Rosado

Rua-Figueroa

Vargas

. Interleukin-10 promoter polymorphisms in patients with systemic lupus erythematosus from the Canary Islands. Int J Immunogenet 2008; 35: 235–242.

36.

Mok

Lanchbury

Chan

Lau

. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1090–1095.

37.

Eskdale

Gallagher

Verweij

Keijsers

Westendorp

Huizinga

. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998; 95: 9465–9470.

38.

Mormann

Rieth

Hua

. Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun 2004; 5: 246–255.

39.

Westendorp

van Dunne

Kirkwood

Helmerhorst

Huizinga

. Optimizing human fertility and survival. Nat Med 2001; 7: 873–873.

40.

De Jong

Westendorp

Eskdale

Uitdehaag

Huizinga

. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum Immunol 2002; 63: 281–285.

41.

Lard

Van Gaalen

Schonkeren

. Association of the -2849 interleukin-10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1841–1848.

42.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

43.

Assmann

Schulte

. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733–737.

44.

International HapMap Project. http://hapmap.ncbi.nlm.nih.gov (2011, accessed December 2011).

45.

Gibson

Edberg

Westendorp

Huizinga

Kimberly

. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001; 166: 3915–3922.

46.

Higuchi

Simple and rapid preparation of samples for PCR. In: Ehrlich

(ed). PCR-technology, principles and applications for DNA amplification, New York: Stockton Press, 1989, pp. 31–38.

47.

Stephens

Smith

Donnelly

. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–989.

48.

Stephens

Donnelly

. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162–1169.

49.

Barrett

Fry

Maller

Daly

. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263–265.

50.

Sham

Curtis

. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97–105.

51.

Beebe

Cua

De Waal

. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev 2002; 13: 403–412.

52.

Lacki

Samborski

Mackiewicz

. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 1997; 16: 275–278.

53.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

54.

O'Neill

Cervera

. Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2010; 24: 841–855.

55.

Yap

Lai

. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol 2010; 2010: 365083–365083. DOI: 10.1155/2010/365083.

56.

Eskdale

Gallagher

Verweij

Keijsers

Westendorp

Huizinga

. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998; 95: 9465–9470.

57.

Nossent

Berden

Swaak

. Renal immunofluorescence and the prediction of renal outcome in patients with proliferative lupus nephritis. Lupus 2000; 9: 504–510.

58.

Eskdale

Keijsers

Huizinga

Gallagher

. Microsatellite alleles and single nucleotide polymorphisms (SNP) combine to form four major haplotype families at the human interleukin-10 (IL-10) locus. Genes Immun 1999; 1: 151–155.